Zhifei Biological subsidiary secures US patent for RSV vaccine technology

Chongqing Zhifei Biological Products Co., Ltd. announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Bio-pharmaceutical Co., Ltd., obtained a U.S. invention patent certificate. The patent, titled "Combined vaccine against human respiratory syncytial virus (RSV) infections and method thereof for inducing immune response," was assigned patent number US12,472,243B2. The patent application date was August 11, 2021, and the authorization announcement date was November 18, 2025. The patent holders are Zhifei Lvzhu and Beijing Jiaotong University, and the patent is estimated to expire on July 29, 2042.

This invention patent was obtained through the collaborative development of an RSV vaccine by Zhifei Lvzhu and Beijing Jiaotong University. The company views this as a breakthrough in international market technical barriers, marking its first patent certificate acquired in the United States and laying a foundation for its global strategic layout.

The acquisition of this patent certificate is not expected to have a significant impact on the company's recent production and operation. However, it is seen as beneficial for further improving the company's intellectual property protection system, fully leveraging its independent intellectual property advantages, promoting technological innovation, advancing the company's international development strategy, and enhancing its core competitiveness.